Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.95
AGN's Cash to Debt is ranked higher than
73% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. AGN: 1.95 )
AGN' s 10-Year Cash to Debt Range
Min: 0.27   Max: 1.95
Current: 1.95

0.27
1.95
Equity to Asset 0.61
AGN's Equity to Asset is ranked higher than
69% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AGN: 0.61 )
AGN' s 10-Year Equity to Asset Range
Min: 0.38   Max: 0.65
Current: 0.61

0.38
0.65
Interest Coverage 24.12
AGN's Interest Coverage is ranked higher than
63% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. AGN: 24.12 )
AGN' s 10-Year Interest Coverage Range
Min: 3.29   Max: 46.04
Current: 24.12

3.29
46.04
F-Score: 7
Z-Score: 10.63
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 26.20
AGN's Operating margin (%) is ranked higher than
94% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. AGN: 26.20 )
AGN' s 10-Year Operating margin (%) Range
Min: -1.34   Max: 28.72
Current: 26.2

-1.34
28.72
Net-margin (%) 18.54
AGN's Net-margin (%) is ranked higher than
91% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. AGN: 18.54 )
AGN' s 10-Year Net-margin (%) Range
Min: -6.96   Max: 20.39
Current: 18.54

-6.96
20.39
ROE (%) 19.66
AGN's ROE (%) is ranked higher than
93% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. AGN: 19.66 )
AGN' s 10-Year ROE (%) Range
Min: -11.73   Max: 41.11
Current: 19.66

-11.73
41.11
ROA (%) 12.02
AGN's ROA (%) is ranked higher than
93% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. AGN: 12.02 )
AGN' s 10-Year ROA (%) Range
Min: -6.6   Max: 18.8
Current: 12.02

-6.6
18.8
ROC (Joel Greenblatt) (%) 122.98
AGN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. AGN: 122.98 )
AGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5   Max: 113.71
Current: 122.98

-5
113.71
Revenue Growth (3Y)(%) 9.30
AGN's Revenue Growth (3Y)(%) is ranked higher than
77% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. AGN: 9.30 )
AGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.1   Max: 19.6
Current: 9.3

-3.1
19.6
EBITDA Growth (3Y)(%) 60.90
AGN's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. AGN: 60.90 )
AGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -46   Max: 96
Current: 60.9

-46
96
» AGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AGN Guru Trades in Q4 2013

Andreas Halvorsen 1,438,989 sh (New)
George Soros 90,000 sh (+20%)
Mario Gabelli 127,769 sh (+0.16%)
Dodge & Cox 3,564 sh (unchged)
Frank Sands Sold Out
Jim Simons Sold Out
Pioneer Investments 819,803 sh (-4.19%)
Ken Fisher 6,882 sh (-4.91%)
Jeremy Grantham 727,994 sh (-19.39%)
Joel Greenblatt 34,897 sh (-45.01%)
Paul Tudor Jones 3,600 sh (-66.36%)
Steven Cohen 139,119 sh (-77.4%)
Ray Dalio 40,719 sh (-81.99%)
» More
Q1 2014

AGN Guru Trades in Q1 2014

Jim Simons 164,456 sh (New)
Bill Ackman 597,431 sh (New)
Paul Tudor Jones 9,987 sh (+177.42%)
Jeremy Grantham 1,101,751 sh (+51.34%)
Pioneer Investments 863,660 sh (+5.35%)
Dodge & Cox 3,564 sh (unchged)
George Soros Sold Out
Andreas Halvorsen Sold Out
Mario Gabelli 126,924 sh (-0.66%)
Ken Fisher 6,685 sh (-2.86%)
Joel Greenblatt 18,843 sh (-46%)
Ray Dalio 18,499 sh (-54.57%)
Steven Cohen 20,480 sh (-85.28%)
» More
Q2 2014

AGN Guru Trades in Q2 2014

Paul Singer 281,700 sh (New)
Jean-Marie Eveillard 30,000 sh (New)
Eric Mindich 901,000 sh (New)
Louis Moore Bacon 60,000 sh (New)
Richard Perry 1,667,625 sh (New)
Jim Chanos 45,300 sh (New)
John Paulson 5,602,000 sh (New)
Andreas Halvorsen 803,369 sh (New)
Bill Ackman 28,878,538 sh (+4733.79%)
Jim Simons 416,395 sh (+153.2%)
Mario Gabelli 131,198 sh (+3.37%)
Steven Cohen 371,500 sh (unchged)
Dodge & Cox 3,564 sh (unchged)
Ray Dalio Sold Out
Pioneer Investments 804,629 sh (-6.83%)
Ken Fisher 6,183 sh (-7.51%)
Jeremy Grantham 973,051 sh (-11.68%)
Joel Greenblatt 16,281 sh (-13.6%)
Paul Tudor Jones 2,900 sh (-70.96%)
» More
Q3 2014

AGN Guru Trades in Q3 2014

Andreas Halvorsen 2,279,736 sh (+183.77%)
Eric Mindich 1,683,251 sh (+86.82%)
Pioneer Investments 823,188 sh (+2.31%)
Bill Ackman 28,878,538 sh (unchged)
Paul Singer Sold Out
Richard Perry Sold Out
Ken Fisher 6,015 sh (-2.72%)
John Paulson 5,377,200 sh (-4.01%)
Mario Gabelli 123,938 sh (-5.53%)
Jeremy Grantham 900,754 sh (-7.43%)
Dodge & Cox 3,264 sh (-8.42%)
Paul Tudor Jones 2,300 sh (-20.69%)
Steven Cohen 274,900 sh (-26%)
Louis Moore Bacon 31,870 sh (-46.88%)
Jim Simons 193,595 sh (-53.51%)
Joel Greenblatt 5,670 sh (-65.17%)
Jim Chanos 15,330 sh (-66.16%)
Jean-Marie Eveillard 10,000 sh (-66.67%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Perry 2014-09-30 Sold Out 7.8%$151.92 - $179.7 $ 212.6328%0
Andreas Halvorsen 2014-09-30 Add 183.77%1.04%$151.92 - $179.7 $ 212.6328%2279736
John Paulson 2014-09-30 Reduce -4.01%0.16%$151.92 - $179.7 $ 212.6328%5377200
Joel Greenblatt 2014-09-30 Reduce -65.17%0.02%$151.92 - $179.7 $ 212.6328%5670
Jean-Marie Eveillard 2014-09-30 Reduce -66.67%0.01%$151.92 - $179.7 $ 212.6328%10000
Bill Ackman 2014-06-30 Add 4733.79%38%$116.63 - $173.95 $ 212.6337%28878538
Richard Perry 2014-06-30 New Buy7.8%$116.63 - $173.95 $ 212.6337%1667625
John Paulson 2014-06-30 New Buy4.1%$116.63 - $173.95 $ 212.6337%5602000
Andreas Halvorsen 2014-06-30 New Buy0.59%$116.63 - $173.95 $ 212.6337%803369
Ray Dalio 2014-06-30 Sold Out 0.02%$116.63 - $173.95 $ 212.6337%0
Jean-Marie Eveillard 2014-06-30 New Buy0.01%$116.63 - $173.95 $ 212.6337%30000
Bill Ackman 2014-03-31 New Buy0.88%$110.28 - $131.43 $ 212.6375%597431
Andreas Halvorsen 2014-03-31 Sold Out 0.75%$110.28 - $131.43 $ 212.6375%0
George Soros 2014-03-31 Sold Out 0.09%$110.28 - $131.43 $ 212.6375%0
Joel Greenblatt 2014-03-31 Reduce -46%0.04%$110.28 - $131.43 $ 212.6375%18843
Ray Dalio 2014-03-31 Reduce -54.57%0.02%$110.28 - $131.43 $ 212.6375%18499
Frank Sands 2013-12-31 Sold Out 1.9%$88.48 - $110.85 $ 212.63123%0
Andreas Halvorsen 2013-12-31 New Buy0.75%$88.48 - $110.85 $ 212.63123%1438989
Ray Dalio 2013-12-31 Reduce -81.99%0.14%$88.48 - $110.85 $ 212.63123%40719
Joel Greenblatt 2013-12-31 Reduce -45.01%0.09%$88.48 - $110.85 $ 212.63123%34897
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Allergan Inc

Ackman's Pershing Square Now Available To The Public
Bill Ackman’s Pershing Square Holdings started trading on the Euronext Amsterdam under the symbol “PSH” on October 13. Daniel Loeb had a similar IPO in 2007 on the London Stock Exchange with his fund, Third Point Offshore (LSE:TPOU, LSE:TPOG, TPNTF). The goal of the IPO is to raise permanent capital to help the activist investor maintain his positions in target companies during times of turbulence. If too many investors have redemption requests in the hedge fund, the manager will not be able to maintain a position of control over all of the companies in the portfolio. Read more...
Bill Ackman's Midas Touch
Outside the investment community, the name of Bill Ackman (Trades, Portfolio) of Pershing Square might not raise as many eyebrows as the name of a guru like Warren Buffett (Trades, Portfolio), but Ackman’s track record is still impressive. He seems to have the Midas touch, even more of one than many of the gurus followed by GuruFocus. Read more...
Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen
Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65. Read more...
Stocks with High Forward Rate of Return, Donald Yacktman’s Measure
Among the criteria Donald Yacktman, conservative value investor who runs the risk-averse Yacktman Asset Management, uses to judge the attractiveness of a stock, he strongly prizes a high “forward rate of return.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 49.60
AGN's P/E(ttm) is ranked higher than
74% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. AGN: 49.60 )
AGN' s 10-Year P/E(ttm) Range
Min: 16.7   Max: 79.22
Current: 49.6

16.7
79.22
P/B 8.90
AGN's P/B is ranked higher than
55% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. AGN: 8.90 )
AGN' s 10-Year P/B Range
Min: 2.4   Max: 15.92
Current: 8.9

2.4
15.92
P/S 9.15
AGN's P/S is ranked higher than
61% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. AGN: 9.15 )
AGN' s 10-Year P/S Range
Min: 2.18   Max: 9.2
Current: 9.15

2.18
9.2
PFCF 44.11
AGN's PFCF is ranked higher than
86% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 44.11 )
AGN' s 10-Year PFCF Range
Min: 16.97   Max: 143.81
Current: 44.11

16.97
143.81
EV-to-EBIT 33.37
AGN's EV-to-EBIT is ranked higher than
76% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. AGN: 33.37 )
AGN' s 10-Year EV-to-EBIT Range
Min: -6103.8   Max: 773.4
Current: 33.37

-6103.8
773.4
PEG 1.80
AGN's PEG is ranked higher than
91% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 1.80 )
AGN' s 10-Year PEG Range
Min: 0.41   Max: 12.32
Current: 1.8

0.41
12.32
Shiller P/E 79.77
AGN's Shiller P/E is ranked higher than
77% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. AGN: 79.77 )
AGN' s 10-Year Shiller P/E Range
Min: 32.89   Max: 118.3
Current: 79.77

32.89
118.3
Current Ratio 3.90
AGN's Current Ratio is ranked higher than
82% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. AGN: 3.90 )
AGN' s 10-Year Current Ratio Range
Min: 0.89   Max: 4.5
Current: 3.9

0.89
4.5
Quick Ratio 3.71
AGN's Quick Ratio is ranked higher than
84% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. AGN: 3.71 )
AGN' s 10-Year Quick Ratio Range
Min: 0.78   Max: 4.26
Current: 3.71

0.78
4.26

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.09
AGN's Dividend Yield is ranked lower than
95% of the 519 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. AGN: 0.09 )
AGN' s 10-Year Dividend Yield Range
Min: 0.09   Max: 0.63
Current: 0.09

0.09
0.63
Dividend Payout 0.05
AGN's Dividend Payout is ranked higher than
99% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 0.05 )
AGN' s 10-Year Dividend Payout Range
Min: 0.04   Max: 6
Current: 0.05

0.04
6
Yield on cost (5-Year) 0.10
AGN's Yield on cost (5-Year) is ranked lower than
95% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. AGN: 0.10 )
AGN' s 10-Year Yield on cost (5-Year) Range
Min: 0.09   Max: 0.63
Current: 0.1

0.09
0.63
Share Buyback Rate 0.70
AGN's Share Buyback Rate is ranked higher than
87% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.30 vs. AGN: 0.70 )
AGN' s 10-Year Share Buyback Rate Range
Min: 1.1   Max: -4.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 120.81
AGN's Price/Net Current Asset Value is ranked higher than
76% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 120.81 )
AGN' s 10-Year Price/Net Current Asset Value Range
Min: 58.67   Max: 438.7
Current: 120.81

58.67
438.7
Price/Tangible Book 22.05
AGN's Price/Tangible Book is ranked higher than
56% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.32 vs. AGN: 22.05 )
AGN' s 10-Year Price/Tangible Book Range
Min: 3.38   Max: 277.05
Current: 22.05

3.38
277.05
Price/DCF (Projected) 3.68
AGN's Price/DCF (Projected) is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. AGN: 3.68 )
AGN' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 6.46
Current: 3.68

1.3
6.46
Price/Median PS Value 1.81
AGN's Price/Median PS Value is ranked higher than
61% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. AGN: 1.81 )
AGN' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 2.3
Current: 1.81

0.31
2.3
Price/Peter Lynch Fair Value 1.98
AGN's Price/Peter Lynch Fair Value is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AGN: 1.98 )
AGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.89   Max: 5.65
Current: 1.98

0.89
5.65
Price/Graham Number 6.90
AGN's Price/Graham Number is ranked higher than
70% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.17 vs. AGN: 6.90 )
AGN' s 10-Year Price/Graham Number Range
Min: 1.58   Max: 60.77
Current: 6.9

1.58
60.77
Earnings Yield (Greenblatt) 3.00
AGN's Earnings Yield (Greenblatt) is ranked higher than
76% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AGN: 3.00 )
AGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.1
Current: 3

0.1
8.1
Forward Rate of Return (Yacktman) 30.85
AGN's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. AGN: 30.85 )
AGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -26.4   Max: 51.2
Current: 30.85

-26.4
51.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, FRX, MRX, ESALF » details
Traded in other countries:AG4.Germany,
Allergan Inc was founded in 1950 and incorporated in Delaware in 1977. The Company is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential. The Company discovers, develops and commercializes specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets. It is engaged in specialty pharmaceutical, biologic and medical device research and development, with global efforts targeting products and technologies related to eye care, skin care, neuromodulators, medical aesthetics, obesity intervention, urology and neurology. The Company operates its business on the basis of two reportable segments specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces a broad range of pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologics products. The medical devices segment produces a broad range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. The Company provides marketing strategy teams to ensure development and execution of a consistent marketing strategy for its products in all geographic regions that share similar distribution channels and customers. The Company faces intense competition from generic drug manufacturers in the United States and internationally. The Company is subject to federal, state, local and foreign environmental laws and regulations.
» More Articles for AGN

Headlines

Articles On GuruFocus.com
Aegean Commences Drilling at Hot Maden Gold-Copper Project, Eastern Turkey Dec 15 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Guru Bill Ackman Is Having a Very Good Year Nov 10 2014 
Aegean Metals Group & Mariana Resources Limited Sign Plan of Arrangement Nov 05 2014 
Aegean Metals Group Inc. Closes Non-Brokered Private Placement with Lead Order Oct 23 2014 
Bill Ackman's New Interview With Bloomberg Oct 13 2014 
Ackman's Pershing Square Now Available To The Public Oct 13 2014 
Bill Ackman's Midas Touch Oct 10 2014 
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
Wallace Weitz's Value Fund Q2 Commentary Oct 06 2014 


More From Other Websites
Spain's Almirall gains on report of Actavis interest Dec 19 2014
Ackman Accused of Insider Trading in Allergan Shareholder Suit Dec 18 2014
AGN SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan,... Dec 18 2014
Lawsuit accuses Ackman, Valeant of insider trading in Allergan stock Dec 18 2014
EQUITY ALERT: The Rosen Law Firm Announces the Filing of Securities Class Action on Behalf of... Dec 18 2014
Elliott sells out its position in Allergan Dec 18 2014
COTCHETT, PITRE & McCARTHY, LLP Files Class Action Lawsuit on Behalf of Persons Who Sold Allergan... Dec 17 2014
Deadline in Lawsuit for Certain Sellers of Allergan, Inc. (AGN) Shares Announced by Shareholders... Dec 17 2014
Allergan downgraded by UBS Dec 17 2014
BOTTINI & BOTTINI, INC. Files Class Action Lawsuit On Behalf Of Persons Who Sold Allergan Stock... Dec 17 2014
Few Allergan execs to keep top jobs in Actavis takeover Dec 16 2014
Great Stocks: Valeant Pharmaceuticals Near Buy Point Dec 16 2014
Actavis Unveils Management Changes Dec 16 2014
Activis to Replace Most Allergan Executives After Deal Dec 16 2014
Companies begging for activist to strike: Cramer Dec 09 2014
Where Could ValueAct Capital's New $1.5 Billion Go? Dec 09 2014
Exclusive - Valeant to drop deal-making in near term to cut debt, boost stock Dec 09 2014
Valeant puts dealmaking on hold to focus on the bottom line Dec 09 2014
Reports: Merck in talks to buy Cubist Dec 07 2014
My 2014 Healthcare Top 10 List Dec 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK